Igor Slukvin

Research Program:

Our research interests focus on understanding the cellular and molecular pathways that lead to the development of hematopoietic and vascular cells from human pluripotent stem cells (hPSCs), as well as advancing induced pluripotent stem cell (iPSC) technologies for HSC transplantation and immunotherapies. We also aim to establish next-generation animal models and tools for assessing precision stem cell therapies. Our work is vital for developing novel sources of cells for bone marrow transplantation, transfusion, and immunotherapies for cancer and AIDS.

Selected Publications:

1. Vodyanik MA, Yu J, Zhang X, Tian S, Stewart R, Thomson JA, Slukvin II. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 2010 Dec 3;7(6):718-29
2. Uenishi G, Jung HS, Kumar A, Park MA, Hadland BK, McLeod E, Raymond M, Moskvin O, Zimmerman CE, Theisen DJ, Swanson S, Tamplin O, Zon LI, Thomson JA, Bernstein ID and Slukvin II. NOTCH Signaling Specifies Arterial-Type Definitive Hemogenic Endothelium from Human Pluripotent Stem Cells. Nature Communications 2018 May 8;9(1):1828.
3. D’Souza SS, Bennett S, Kumar A, Kelnhofer LE, Weinfurter J, Suknuntha K, Coonen J, Mejia A, Simmons H, Golos T, Hematti P, Capitini CM, Reynolds MR, Slukvin II. Transplantation of T-cell receptor α/β-depleted allogeneic bone marrow in nonhuman primates. Exp Hematol. 2021 Jan;93:44-51.
4. Zhang J, Webster S, Duffin B, Bernstein MN, Steill J, Swanson S, Forsberg MH, Bolin J, Brown ME, Majumder A, Capitini CM, Stewart R, Thomson JA, Slukvin II. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Reports. Stem Cell Reports. 2023 Feb 14;18(2):585-596.
5. Jung HS, Sedzro DM, Liu P, Slukvin II. A NOTCH4 intron 28 regulatory element controls arterial specification and lymphoid development from hPSCs, Blood VTH, Volume 2, Issue 2, 2025,100046, ISSN 2950-3272.